Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Consensus Recommendation of “Strong Buy” from Analysts

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) have been assigned a consensus rating of “Strong Buy” from the six research firms that are currently covering the firm, Marketbeat reports. Three analysts have rated the stock with a buy recommendation and three have issued a strong buy recommendation on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $34.00.

Several research analysts have recently weighed in on the company. Zacks Research upgraded Catalyst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 3rd. Truist Financial upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, March 25th. Cantor Fitzgerald raised Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Friday, March 27th. Weiss Ratings restated a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a report on Friday, March 27th. Finally, Citigroup raised their target price on Catalyst Pharmaceuticals from $33.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, March 3rd.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of CPRX. Parkside Financial Bank & Trust grew its stake in shares of Catalyst Pharmaceuticals by 17.6% in the 4th quarter. Parkside Financial Bank & Trust now owns 3,138 shares of the biopharmaceutical company’s stock valued at $73,000 after buying an additional 469 shares during the period. Oregon Public Employees Retirement Fund raised its position in shares of Catalyst Pharmaceuticals by 1.8% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 26,428 shares of the biopharmaceutical company’s stock valued at $617,000 after buying an additional 472 shares during the period. Jones Financial Companies Lllp lifted its holdings in Catalyst Pharmaceuticals by 14.0% in the third quarter. Jones Financial Companies Lllp now owns 4,061 shares of the biopharmaceutical company’s stock valued at $79,000 after acquiring an additional 498 shares during the last quarter. Lifestyle Asset Management Inc. lifted its holdings in Catalyst Pharmaceuticals by 3.4% in the fourth quarter. Lifestyle Asset Management Inc. now owns 16,835 shares of the biopharmaceutical company’s stock valued at $393,000 after acquiring an additional 553 shares during the last quarter. Finally, Smartleaf Asset Management LLC grew its position in Catalyst Pharmaceuticals by 55.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock worth $41,000 after acquiring an additional 630 shares during the period. 79.22% of the stock is currently owned by institutional investors and hedge funds.

Catalyst Pharmaceuticals Trading Down 0.5%

CPRX opened at $24.69 on Friday. Catalyst Pharmaceuticals has a twelve month low of $19.05 and a twelve month high of $26.58. The firm has a market capitalization of $3.02 billion, a PE ratio of 14.61, a PEG ratio of 0.72 and a beta of 0.67. The firm’s 50-day moving average price is $24.08 and its 200 day moving average price is $22.80.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).